ClinicalTrials.gg
Not yet recruitingNCT07689110inspira-rctUpdated Jul 8, 2026

Progressive Pressure Support Reduction as Inspiratory Muscle Endurance Training in Mechanically Ventilated Patients

An interventional study of Progressive Pressure Support Reduction (IRT-PS) and Standard ICU Care in Respiratory Muscle Weakness, Mechanical Ventilation Weaning and Physiotherapy, sponsored by University of Santiago de Compostela. Not yet recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-08.

Sponsored by University of Santiago de Compostela · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Muscle Weakness with a site in Spain — 3 open to participants now, 5 under way, none of them phase 3. Muscle Weakness · Spain.

Planned enrollment
10th of 19
60 · median 60
Started
2026
with 1 other
No phase
15 of 27
2 open now
Registered
26th of 27
by date

Among the 27 studies in Muscle Weakness with a site in Spain, this one is the 10th largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2026, is one of 15 with no phase, and was the 26th registered.

Muscle Weakness

478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.

Browse Muscle Weakness studies →

Open to participants now

3 of the 27 studies in Muscle Weakness with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscle Weakness with a site in Spain, or all of them as a file.
02

Study summary

Mechanical ventilation causes rapid diaphragm muscle atrophy, detectable within 18 hours of ventilator support, which is a major contributor to weaning failure and prolonged ICU stay.

This randomized controlled trial tests whether a physiotherapist-guided inspiratory endurance training program - achieved by progressively reducing pressure support (PS) levels on the ventilator - can preserve or improve inspiratory muscle strength and diaphragm structure in critically ill adults on mechanical ventilation, compared to standard ICU care.

Participants will be randomly assigned to one of two groups. The intervention group will receive twice-daily training sessions (weekdays only) in which the physiotherapist gradually reduces PS by up to 50% of the baseline level, causing the patient to breathe with greater muscular effort - equivalent to progressive endurance exercise for the diaphragm. The control group will receive standard weaning care as directed by the attending intensivist.

The primary outcome is maximal inspiratory pressure (PImax) at day 7. Secondary outcomes include diaphragm thickening fraction measured by ultrasound, time to successful extubation, weaning success rate, and mortality.

All measurements are performed by the ICU physician (blinded to group allocation) using airway occlusion maneuvers recorded on the ventilator and diaphragm ultrasound, following a standardized protocol.

03

Conditions studied

  • Respiratory Muscle Weakness
  • Mechanical Ventilation Weaning
  • Physiotherapy
  • Endurance Training

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years
  2. Admitted to ICU with invasive mechanical ventilation for more than 48 hours at the time of randomization
  3. Expected to remain intubated for at least 24 additional hours, at the discretion of the attending intensivist
  4. Active pressure support ventilation (PSV) mode with PS level ≥ 5 cmH2O
  5. Richmond Agitation-Sedation Scale (RASS) score between -1 and +1
  6. Arterial pH ≥ 7.35 and serum lactate ≤ 2.0 mmol/L
  7. Peripheral oxygen saturation (SpO2) ≥ 90% with current FiO2
  8. obtained from patient or legal representative

Exclusion criteria

Exclusion Criteria:

  1. Neurological condition affecting central respiratory control (high cervical spinal cord injury, ALS, myasthenia gravis, active Guillain-Barré syndrome)
  2. Established tracheostomy at the time of inclusion
  3. Restriction on head-of-bed elevation to ≥ 30 degrees
  4. Decision to limit therapeutic effort (LET) or \< 48 hours
  5. Active hemodynamic instability (requirement for ≥ 2 vasopressors or vasopressor adjustment within the last 6 hours)
  6. Multiple rib fractures or undrained pneumothorax
  7. Simultaneous participation in another interventional clinical trial
  8. Previous inclusion in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Inspiratory Resistance Training (IRT-PS)

    Physiotherapist-guided inspiratory endurance training by progressive pressure support reduction (25-50% of baseline PS), 1-3 sets of 5-15 minutes, twice daily on weekdays, for up to 14 days or until extubation. Target: Borg CR10 score 3-5. P0.1 monitored continuously; sessions stopped if P0.1 \> 4 cmH2O sustained \> 2 minutes.

    Behavioral: Progressive Pressure Support Reduction (IRT-PS)

  • Active comparator
    Standard Care (Usual Care)

    Conventional weaning as directed by the attending intensivist, without a structured inspiratory muscle training program. Conventional physiotherapy (early mobilization, chest physiotherapy) is permitted in both groups.

    Other: Standard ICU Care

Interventions

  • BehavioralProgressive Pressure Support Reduction (IRT-PS)

    Progressive reduction of pressure support (PS) during ventilator-assisted breathing, performed by a physiotherapist twice daily (weekdays only). Sessions consist of 1-3 sets of 5-15 minutes with 2-minute rest intervals at baseline PS. PS is reduced by 25% initially up to a maximum of 50% of baseline (minimum 5 cmH2O) for PS ≥10 cmH2O; by 1-2 cmH2O for PS 5-9 cmH2O; and by 1 cmH2O down to 0 cmH2O for PS \<5 cmH2O. Target perceived exertion: Borg CR10 3-5. P0.1 monitored continuously; session stopped if P0.1 \>4 cmH2O sustained \>2 minutes (Goligher et al. criteria). Safety stop criteria: RR \>35 rpm, SpO2 \<90%, HR \>120 bpm.

  • OtherStandard ICU Care

    Conventional weaning managed by the attending intensivist according to standard clinical practice, without a structured inspiratory muscle training protocol. Conventional physiotherapy (early mobilization, chest physiotherapy) permitted in both groups.

06

What researchers measure

Primary outcomes

  1. Maximal Inspiratory Pressure (PImax)

    Measured by manual airway occlusion at end-expiration with pressure curve recorded on the ventilator. Standardized verbal instruction given to the patient. Best of 3 valid maneuvers recorded. Performed by the ICU physician blinded to group allocation.

    Time frame: Day 7 from randomization

Secondary outcomes

  1. Diaphragm Thickening Fraction (DTF)

    measured by ultrasound (linear probe 7-15 MHz, zone of apposition, M-mode, average of 3 cycles). Performed by ICU physician per standardized protocol.

    Time frame: Days 0, 3, 7 and 14 from randomization

  2. P0.1 (Airway Occlusion Pressure at 100ms

    respiratory drive indicator, read directly from ventilator display

    Time frame: Baseline and days 3, 7 and 14; and at start, mid and end of each training session (intervention group)

  3. Time to Successful Extubation

    hours from randomization to extubation without reintubation within 48 hours

    Time frame: From randomization until extubation, up to 14 days

  4. Weaning Success Rate

    proportion of patients extubated without reintubation within 48 hours

    Time frame: Days 7 and 14 from randomization

  5. Sustained Pressure Support Reduction

    difference in cmH2O between baseline PS at Day 0 and Day 7

    Time frame: days 1, 3, 5 and 7 from randomization

  6. Total Days on Mechanical Ventilation

    Time frame: From randomization until ICU discharge, up to 30 days

  7. ICU Mortality

    Time frame: At the time of ICU discharge (up to 24 weeks)

  8. 30-day Mortality

    Time frame: Day 30 from randomization

  9. ICU Readmission at 30 days

    Time frame: Day 30 from randomization

  10. Borg CR10 Score during training session

    perceived respiratory exertion (0-10)

    Time frame: Periprocedural (from the start of the session until 30 minutes post-intervention)

  11. Adverse events during training sessions

    episodes of RR \>35, SpO2 \<90%, HR \>120 bpm

    Time frame: Periprocedural (from the start of the session until 30 minutes post-intervention)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 200 non-industry interventional studies with no phase under Muscle Weakness, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 14 months is above that.

Counting every sponsor, half of 212 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2026
First posted
Jul 8, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Mar 30, 2028
Last update
Jul 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07689110
Lead sponsor
University of Santiago de Compostela
Responsible party
ricardo miguel rodrigues gomes (Asociate Profesor, University of Vigo) — Principal investigator
First posted
Jul 8, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Mar 30, 2028 (estimated)
Last update
Jul 8, 2026

Study contacts

Ricardo Miguel Rodrigues-Gomes
Contact
ric.mr.gomes@gmail.com
+34618060702

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion